Utilizing Corporate Portfolio Management to Stop Investile Dysfunction
 Anand Sanwal, Managing Director, Brilliont; Former VP, Investment Optimization & Strategic Business Analysis, American Express
|
Portfolio Management in the Pharmaceutical Commercialization Space
 Poplin Kroese, Senior Analyst, Portfolio Management Strategy Deployment, Merck
|
Integrating Value into the Portfolio Decision-Making Framework
 Jean Lee, Director, WWD Portfolio Management, Pfizer; Co-developed with Lori S. Shafner, Vice President, Portfolio and Project Management, Pfizer |
Valuing a Diverse Portfolio: The Move from Selling Medicines to Promoting Health
 Marilyn Metcalf, Ph.D., Director, Quantitative and Decision Sciences, GlaxoSmithKline |
Evolution of Resource Management Capability at a Large Biotechnology Company
 Matthew Riddell, M.B.A., Associate Director, Research & Development Planning & Operations, Program & Alliance Management, Biogen Idec
|
Cost-Risk-Value Optimization – Enabling Drug Developers to “Do the right thing”
 Stephen A. Williams, Ph.D., Partner, Decisionability LLC; Former Vice President and Worldwide Head of Clinical Technology, Pfizer
|
Strategic Resource Management: Go Beyond Fancy Charts and Truly Impact Strategic Business Decisions
Christopher Beck, Vice President, Program Resources and Decision Support, Shire Pharmaceuticals
|
Successful Portfolio Management within Discovery at AstraZeneca
 Richard Lawson, Ph.D., Global Head of Discovery Decision Support, Discovery Strategy and Performance, AstraZeneca Pharmaceuticals, Inc.
|
Development Program Prioritization-Allocating Limited Resources in Any Business Environment
 Len Falsone, PE, Economics Manager, EP Americas, Shell Exlporation and Production Company |
Aligning Strategic Capacity Management with Business Development in Healthcare Product Safety
 Colin Cornhill, Senior Director, BRM Integration & Capacity Management, Johnson & Johnson Pharmaceutical R&D
|